255 related articles for article (PubMed ID: 18301078)
1. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count.
Stebbing J; Powles T; Bower M
AIDS; 2008 Feb; 22(4):551-2. PubMed ID: 18301078
[No Abstract] [Full Text] [Related]
2. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
3. Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Ahilasamy N
Int J STD AIDS; 2008 Nov; 19(11):786-8. PubMed ID: 18931277
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of AIDS-associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3).
Mani D; Neil N; Israel R; Aboulafia DM
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(5):279-85. PubMed ID: 19721098
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load.
Maurer T; Ponte M; Leslie K
N Engl J Med; 2007 Sep; 357(13):1352-3. PubMed ID: 17898112
[No Abstract] [Full Text] [Related]
6. Kaposi's sarcoma-associated immune reconstitution following highly active antiretroviral treatment initiation.
Chan DJ
Int J STD AIDS; 2006 Jan; 17(1):72. PubMed ID: 16409689
[No Abstract] [Full Text] [Related]
7. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
8. Peculiar type of KS emerges in healthier individuals.
Proj Inf Perspect; 2008 Dec; (47):13-4. PubMed ID: 19230234
[No Abstract] [Full Text] [Related]
9. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
Bower M; Weir J; Francis N; Newsom-Davis T; Powles S; Crook T; Boffito M; Gazzard B; Nelson M
AIDS; 2009 Aug; 23(13):1701-6. PubMed ID: 19550283
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population.
Bravo IM; Correnti M; Escalona L; Perrone M; Brito A; Tovar V; Rivera H
Med Oral Patol Oral Cir Bucal; 2006 Jan; 11(1):E33-9. PubMed ID: 16388291
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of HIV-related Kaposi's sarcoma].
Reyners AK; Sprenger HG; Suurmeijer AJ; van der Graaf WT
Ned Tijdschr Geneeskd; 2006 Mar; 150(11):589-93. PubMed ID: 16610494
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Kaposi's sarcoma.
Von Roenn JH; Cianfrocca M
Cancer Treat Res; 2001; 104():127-48. PubMed ID: 11191125
[No Abstract] [Full Text] [Related]
13. Presentation and survival of patients with AIDS-related Kaposi's sarcoma in Jos, Nigeria.
Agaba PA; Sule HM; Ojoh RO; Hassan Z; Apena L; Mu'azu MA; Badung B; Agbaji OO; Idoko JA; Kanki P
Int J STD AIDS; 2009 Jun; 20(6):410-3. PubMed ID: 19451327
[TBL] [Abstract][Full Text] [Related]
14. Highly active antiretroviral therapy for the treatment of Kaposi's sarcoma associated with primary human immunodeficiency virus type-1 infection.
Genka I; Yasuoka A; Saitoh K; Oka S
Jpn J Infect Dis; 2000 Aug; 53(4):166-7. PubMed ID: 11056560
[No Abstract] [Full Text] [Related]
15. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Noy A; Scadden DT; Lee J; Dezube BJ; Aboulafia D; Tulpule A; Walmsley S; Gill P
J Clin Oncol; 2005 Feb; 23(5):990-8. PubMed ID: 15598977
[TBL] [Abstract][Full Text] [Related]
16. Management of Kaposi's sarcoma in resource-limited settings in the era of HAART.
Lynen L; Zolfo M; Huyst V; Louis F; Barnardt P; Van de Velde A; De Schacht C; Colebunders R
AIDS Rev; 2005; 7(1):13-21. PubMed ID: 15875657
[TBL] [Abstract][Full Text] [Related]
17. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
Loke WC; Spittle MF; Mitchell S; Kulasegaram R
Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
[TBL] [Abstract][Full Text] [Related]
18. Kaposi's sarcoma in HIV-infected women and men in Nigeria.
Ibekwe PU; Ogunbiyi OA; Ogun GO; George OA
AIDS Patient Care STDS; 2011 Nov; 25(11):635-7. PubMed ID: 21967494
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma of the tongue.
Andres C; Hofmann H; Ring J
J Eur Acad Dermatol Venereol; 2010 Jan; 24(1):99-100. PubMed ID: 19522709
[No Abstract] [Full Text] [Related]
20. Response to: a retrospective analysis of AIDS-associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3).
Maurer T; Leslie K; Unemori P
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(2):73. PubMed ID: 20484734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
